Article Text

PDF
When the Guillain-Barré patient fails to respond to treatment
  1. J B Winer
  1. Consultant Neurologist and Honorary Senior Lecturer in Neurology, University Hospital Birmingham, Edgbaston, Birmingham B15 2TH, UK; j.b.winer@bham.ac.uk

    Abstract

    Most patients with Guillain-Barré syndrome (GBS) respond to treatment with intravenous immunoglobulin, but it is not uncommon for some to continue to deteriorate for a period after treatment has been started. This may reflect the natural history of the disease, or an error in diagnosis. This article reflects my own view of what to do in this situation, with a review of what few data there are to guide decision making.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Linked Articles

    • Editor’s choice
      Charles Warlow